Vivek Mishra works as an Assistant Editor with Eastern Eye and has over 13 years of experience in journalism. His areas of interest include politics, international affairs, current events, and sports. With a background in newsroom operations and editorial planning, he has reported and edited stories on major national and global developments.
Borussia Dortmund secured a crucial 1-0 victory over Paris Saint-Germain in the first leg of their Champions League semi-final encounter, with Niclas Fuellkrug emerging as the hero of the night.
Fuellkrug's decisive strike, executed in the 36th minute, came off a pinpoint pass from centre-back Nico Schlotterbeck.
This triumph marked Dortmund's bid to return to the final for the first time since their 2013 victory.
The match showcased Dortmund's resilience as they faced off against their heavily favoured opponents.
Despite PSG's array of talent, Dortmund's determination shone through, exemplified by Fuellkrug's performance.
Playing in his debut Champions League season at the age of 31, Fuellkrug's journey to this moment epitomised the underdog spirit driving Dortmund forward.
PSG, led by the dynamic Kylian Mbappe, struggled to find their rhythm against Dortmund's disciplined defence.
Despite hitting the post twice in quick succession during the second half, PSG failed to capitalise on their chances.
Dortmund's manager, Edin Terzic, had acknowledged PSG's pedigree prior to the match, yet Dortmund's tenacity on the field proved formidable.
The contrast between the two clubs was stark, with PSG boasting global superstars like Mbappe, while Dortmund relied on the experience and determination of players like Fuellkrug.
The passionate home crowd fuelled Dortmund's momentum, with every touch by Mbappe met with boos and whistles.
Jadon Sancho's standout performance down the right flank added to Dortmund's attacking threat, while Marcel Sabitzer and Julian Brandt also posed significant challenges for PSG's defence.
Despite PSG's attacking riches, they struggled to create clear-cut opportunities, recording zero shots on target in the opening half.
The second half saw PSG spring to life, with Mbappe and former Dortmund player Achraf Hakimi both striking the woodwork. However, PSG's efforts were thwarted by Dortmund's resolute defence, exemplified by some desperate last-ditch clearances.
The victory not only bolstered Dortmund's hopes of reaching the final but also ensured an extra Champions League place for Germany next season, thanks to Tuesday's draw between Bayern Munich and Real Madrid in the other semi-final.
This guaranteed Dortmund's place in the competition for the upcoming season, adding further significance to their triumph on the night.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.